Toward personalized treatment in multiple myeloma based on molecular characteristics
نویسندگان
چکیده
منابع مشابه
Treatment of Multiple Myeloma
Les traitements classiques de myelome multiple et les schemas differents proposes ont ete mis en revue. La poly chimiotherapie de la maladie avec une com-binaison de cyclophosphamide, B.C.N.U. Alkeran, Perdnisone et Vincristine a donnee une meilleur Resultat ceci surtout dans les formes graves et rapidement progressive de la maladie. D'autres sehemas therapeutiques sont en cours.
متن کاملToward personalized treatment in psychiatry.
I n recent years, there has been, inspired by developments in other areas of medicine like oncology, an increasing interest in the potential possibilities of personalized medicine in psychiatry. One of the motivating factors behind this interest in the field of mood disorders is the growing awareness among clinicians and researchers that the " one size fits all " approach to the treatment of ma...
متن کاملMolecular predictors in glioblastoma: toward personalized therapy.
Recent therapeutic advances have improved standard treatment for patients with newly diagnosed glioblastoma. Unfortunately, even with these improvements, only a fraction of patients derive significant benefit and experience prolonged survival. These findings are consistent with long-standing clinical and recent molecular evidence that subtypes of glioblastoma exist with differing survival rates...
متن کاملMultiple Myeloma Update
This literature review presents the most recent developments in the management of multiple myeloma, which is characterized by the presence of abnormal plasma cells (myeloma cells) that accumulate into the bone marrow. Aspects related to pathophysiology, clinical manifestations, laboratory, study and treatment are described. These pieces of information are necessary to accomplish a better ...
متن کاملMaintenance treatment in multiple myeloma.
Maintenance chemotherapy has failed to demonstrate any benefit [1, 2]. Corticosteroid maintenance was found to prolong the duration of response; however, the effect on survival was controversial [3, 4]. Interferon-a represented a great hope in the 1980s but metaanalysis of randomized trials showed a modest increase in progression-free survival (PFS) and a minimal benefit in overall survival (OS...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2019
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood-2018-09-825331